Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 3/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18083765 | 0.80 | CHRM3 (0.53) | LMNAGAAPTGESKCNK3KCNK9 | |
| SCHEMBL18083728 | 0.78 | KCNK3 (0.53) | LMNAGAAPTGESKCNK3KCNK9 | |
| SCHEMBL18083711 | 0.77 | ABL1 (0.49) | LMNAGAAPTGESKCNK3KCNK9 | |
| SCHEMBL18083726 | 0.75 | GLS (0.45) | PTGESTP53RXFP1 | |
| SCHEMBL27486980 | 0.73 | MEN1 (0.63) | LMNAGAAPTGESTP53SMN1; SMN2 | |
| SCHEMBL30417052 | 0.73 | MEN1 (0.63) | LMNAGAAPTGESTP53SMN1; SMN2 | |
| SCHEMBL30416204 | 0.73 | DEGS1 (0.60) | LMNAGAAPTGESKCNK3KCNK9 | |
| SCHEMBL26405664 | 0.73 | PTGES (0.56) | LMNAGAAPTGESKCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL30416887 | 0.72 | MEN1 (0.61) | LMNAGAAPTGESPTGS1TP53 | |
| SCHEMBL25383706 | 0.72 | PTGS1 (0.61) | LMNAGAAPTGESKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271348-B1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016146220-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| EP-3070084-A1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | FYN, LCK, LYN | LMNA 4626/4885GAA 3549/4885PTGES 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.